Compare FGBI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FGBI | MOLN |
|---|---|---|
| Founded | 1934 | 2004 |
| Country | United States | Switzerland |
| Employees | 346 | 134 |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.6M | 143.3M |
| IPO Year | N/A | 2021 |
| Metric | FGBI | MOLN |
|---|---|---|
| Price | $10.81 | $3.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 22.5K | 3.6K |
| Earning Date | 04-27-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $567.70 | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.31 | $3.41 |
| 52 Week High | $11.02 | $5.36 |
| Indicator | FGBI | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 45.21 |
| Support Level | $7.98 | $3.61 |
| Resistance Level | N/A | $3.96 |
| Average True Range (ATR) | 0.42 | 0.13 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 75.66 | 33.33 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.